Mirae Asset Global Investments Co. Ltd. Has $1.27 Million Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Mirae Asset Global Investments Co. Ltd. lowered its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) by 57.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,794 shares of the company's stock after selling 59,588 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.15% of Fulgent Genetics worth $1,266,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of FLGT. Trellus Management Company LLC acquired a new position in Fulgent Genetics during the third quarter worth about $1,152,000. Mutual Advisors LLC raised its position in shares of Fulgent Genetics by 5.2% during the third quarter. Mutual Advisors LLC now owns 9,370 shares of the company's stock worth $251,000 after purchasing an additional 462 shares during the period. Campbell & CO Investment Adviser LLC boosted its position in shares of Fulgent Genetics by 461.7% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 51,700 shares of the company's stock valued at $1,382,000 after purchasing an additional 42,495 shares during the period. Illinois Municipal Retirement Fund purchased a new position in Fulgent Genetics in the 3rd quarter worth about $317,000. Finally, Brandywine Global Investment Management LLC acquired a new stake in Fulgent Genetics during the 3rd quarter worth about $2,430,000. Institutional investors own 48.06% of the company's stock.

Fulgent Genetics Stock Performance

Shares of NASDAQ FLGT traded up $0.08 during trading hours on Tuesday, hitting $20.64. The stock had a trading volume of 144,244 shares, compared to its average volume of 201,056. The company has a market capitalization of $617.14 million, a P/E ratio of -3.71 and a beta of 1.43. The firm's 50-day moving average price is $22.55 and its two-hundred day moving average price is $25.29. Fulgent Genetics, Inc. has a 52 week low of $19.88 and a 52 week high of $44.09.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.61. The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative net margin of 58.03% and a negative return on equity of 3.04%. As a group, analysts expect that Fulgent Genetics, Inc. will post -2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their target price on shares of Fulgent Genetics from $28.00 to $25.00 and set a "neutral" rating for the company in a report on Wednesday, March 6th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.